Earlier this year, it also formed a partnership with Novartis to pair its PSMA imaging agent Pylarify (piflufolastat F18) diagnostic, with the Swiss pharma's prostate cancer radiotherapy Pluvicto ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback